Evaluating Regenxbio: Insights From 9 Financial Analysts
Portfolio Pulse from Benzinga Insights
Over the past three months, 9 analysts have evaluated Regenxbio (NASDAQ:RGNX), showing a range of sentiments from bullish to bearish. The average 12-month price target has increased by 7.25% to $40.11. Analysts have recently raised their ratings and price targets, reflecting positive sentiment despite the company's financial challenges.
May 15, 2024 | 7:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regenxbio has received mixed analyst ratings over the past three months, with a recent increase in the average 12-month price target to $40.11. Analysts have raised their ratings and price targets, indicating positive sentiment despite financial challenges.
The increase in the average 12-month price target and the majority of recent ratings being bullish suggest a positive short-term impact on Regenxbio's stock price. However, financial challenges such as declining revenue and low ROE and ROA may temper this optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100